Fly Intel: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Protagonist Therapeutics (PTGX) downgraded to Neutral from Overweight at JPMorgan with analyst Anupam Rama citing Friday's announcement of lead asset rusfertide being placed on clinical hold. 2. Lear (LEA) downgraded to Hold from Buy at Jefferies with analyst David Kelley saying he is lowering his tier 1 supplier estimates for Q3, Q4 and 2022. 3. Texas Instruments (TXN) downgraded to Neutral from Buy at Longbow with analyst Nikolay Todorov seeing signs of less constrained inventory accumulating at semiconductor customers and recommending investors "turn more selective and focus on bottleneck components and suppliers with greater upward estimate revision potential." 4. Prologis (PLD) and Equity Lifestyle (ELS) downgraded to In Line from Outperform at Evercore ISI. 5. Upstart (UPST) downgraded to Neutral from Buy at Citi with analyst Peter Christiansen saying while he thinks the narrative is likely to remain positive with continued loan growth momentum and volumes materializing in autos in 2022, the stock has risen 644% to be one of the top FinTech performers year-to-date. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.